Вопросы Патогенеза Опорно-Двигательных Осложнений Акромегалии
Keywords:
патогенез, акромегалия, опорно-двигательные осложнения
Abstract
Патогенез опорно-двигательных осложнений (ОДО) акромегалии сложен, при этом в нём задействованы и избыток гормона роста/инсулиноподобного гормона роста-1 (ГР/ИФР-1) и вторичные дегенеративные изменения. Известно, что при акромегалии происходит нарушение костного обмена с повышением резорбтивных процессов, по сравнению с синтезом. Несмотря на достаточно высокую частоту костно-мышечных проявлений при акромегалии и на то, что почти у всех больных акромегалией развиваются объективные или субъективные признаки артропатии, данные о них остаются спорными. Ранняя диагностика и правильно выбранное лечение, как залог предотвращения развития необратимых осложнений и улучшения качества жизни больных, страдающих этими заболеваниями, остаются приоритетной задачей современной эндокринологии, требующей своей реализации.
References
1. Дедова И.И., Мельниченко Г.А. Эндокринология. Российские клинические рекомендации. — М.: ГЭОТАР-Медиа; 2016, С. 14-55.
2. Молитвословова Н. Н. ФГУ Эндокринологический научный центр Минздравсоцразвития Российской Федерации // Проблемы эндокринологии. - 2011. - №57(1).- С. 46-59.
3. Потешкин Ю.Е. «Композиционный состав тела (тощая, жировая и костная ткань) и минеральная плотность костей у больных акромегалией» Диссерт на соиск. Уч. Ст. канд.м.н., Москва, 2014, стр 13-15
4. Пронин В.С., Пронин Е.В. Международные консенсусные соглашения по диагностике и лечению акромегалии // Аналитические обзоры: Эндокринология: новости, мнения, обучение. - 2019. - Том 8, № 1.
5. Самородская И.В., Болотова Е. В., Бойцов С. А. Актуальные вопросы классификации ожирения //Cardiovascular Therapy and Prevention, 2015; 14(4): 103–110
6. Холикова А.О. Соматотропиномы: клинико-эпидемиологические аспекты, частота осложнений, оценка эффективности лечения по Республике Узбекистан //Автореферат на диссертационную работу. - 2019. - С. 7-12.
7. Чих И.Д., Триголосова И.В., Древаль А.В., Триголосов А.В. Новообразования при акромегалии // Альманах клинической медицины. 2016.- №44 (5). - С. 568–579.
8. Abreu A, Tovar AP, Castellanos R, Valenzuela A, Giraldo CM, Pinedo AC, Guerrero DP, Barrera CA, Franco HI, Ribeiro-Oliveira A Jr, Vilar L, Jallad RS, Duarte FG, Gadelha M, Boguszewski CL, Abucham J, Naves LA, Musolino NR, de Faria ME, Rossato C, Bronstein MD (2016) Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary 19(4):448–457
9. Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, Thorsson AV, Carroll PV, Korbonits M, Benediktsson R (2015) The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. Eur J Endocrinol 173(5):655–664.
10. Ajmal A, Haghshenas A, Attarian S, Barake M, Tritos NA, Klibanski A, Miller KK & Nachtigall LB. The effect of somatostatin analogs on vitamin D and calcium concentrations in patients with acromegaly. Pituitary 2014 17 366–373
11. Altinova AE, Ozkan C, Akturk M, Gulbahar O, Yalcin M, Cakir N & Toruner FB. Vitamin D-binding protein and free vitamin Dconcentrations in acromegaly. Endocrine 2016 52 374–379.
12. Andrea Giustina, Gherardo Mazziotti, and Ernesto Canalis Growth Hormone, Insulin-Like Growth Factors, and the Skeleton/ Endocr Rev. 2008 Aug; 29(5): 535–559.
13. Ariel L. Barkan. Acromegalic Arthropathy// Pituitary 4: 263–264, 2001.
14. Arosio M, Emerging trends in the diagnosis and treatment of acromegaly in Canada // Clin Endocrinol (Oxf). - 2013.- Jul; 79(1).- С.79-85.
15. Arosio M, Reimondo G, Malchiodi E et al (2012) Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 167(2):189–198
16. Belaya Z, Grebennikova T, Melnichenko G, Nikitin A, Solodovnikov A, Brovkina O, Grigoriev A, Rozhinskaya L, Lutsenko A & Dedov I. Effects of active acromegaly on bone mRNA and microRNA expression patterns. European Journal of Endocrinology 2018 178 353–364.
17. Ben-Shlomo A., M. C. Sheppard, J. M. Stephens, S. Pulgar, and S. Melmed Clinical, quality of life, and economic value of acromegaly disease control/ Pituitary. 2011 September; 14(3): 284–294.
18. Biermasz N. R., Van Thiel S. W., Pereira A. M. et al., “Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 11, pp. 5369–5376, 2004.
19. Burghardt AJ, Issever AS, Schwartz AV , et al. . High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab . 2010;95(11):5045–5055.
20. Canalis E The fate of circulating osteoblasts. N Engl J Med 2005; 352:2014–2016
21. Capatina C, Wass J.A. 60 years of neuroendocrinology: acromegaly// J Endocrinol. - 2015.-№ 226.- С.141–160.
22. Colao A, Grasso LFS, Giustina A, Melmed S . et all. Acromegaly// Nat Rev Dis Primers.- 2019.- № 5(1).- С.20-24
23. Constantin T, Tangpricha V, Shah R, Oyesiku NM, Ioachimescu OC, Ritchie J & Ioachimescu AG. Calcium and bone turnover markers in acromegaly: a prospective, controlled study. Journal of Clinical Endocrinology and Metabolism 2017 102 2416–2424.
24. Dal J, Feldt-Rasmussen U, Andersen M, Kristensen LØ. et all. Acromegaly incidence, prevalence, complications, and long-term prognosis: a nationwide cohort study // Eur J Endocrinol.- 2016.- 175(3). С.181-190.
25. Dal J, List E.O, Jørgensen JO, Berryman D.E Glucose and fat metabolism in acromegaly: from mice models to patient care// Neuroendocrinology.- 2016.-№103(1).- С.96–105.
26. Dalle Carbonare L, Micheletti V, Cosaro E, Valenti MT, Mottes M, Francia G & Davi MV. Bone histomorphometry in acromegaly patients with fragility vertebral fractures. Pituitary 2018 21 56–2164.
27. Dalzell N, Kaptoge S, Morris N, et al. Bonemicro-architecture and determinants of strength intheradius and tibia: age-relatedchanges in a population-based study of normal adults measured with highresolution pQCT. Osteoporos Int. 2009;20(10):1683–1694.
28. De Mambro VE, Le PT, Guntur AR, Maridas DE, Canalis E, Nagano K, Baron R, Clemmons DR & Rosen CJ. Igfbp2 deletion in ovariectomized mice enhances energy expenditure but accelerates bone loss. Endocrinology 2015 156 4129–4140.
29. Dreval A.V., Trigolosova I.V., Misnikova I.V. et all. Prevalence of diabetes mellitus in patients with acromegaly// Endocr Connect.- 2014.-№ 3.-С.93–98
30. Gadelha MR, Kasuki L, Lim DST, Fleseriu M. Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update// Endocr Rev.- 2019.- 40(1).-С.268-332.
31. Giuseppina P., Graziella B., Laura I. et al., “Prevalence of osteoporosis and vertebral fractures in acromegalic patients,” Clinical Cases in Mineral and Bone Metabolism, vol. 8, no. 3, pp. 37–43, 2011.
32. Giustina A, Chanson P, Bronstein MD, Klibanski A. et all. A consensus on criteria for cure of acromegaly// J Clin Endocrinol Metab. - 2010.-95 (7).-С. 3141–3148.
33. Giustina, A. et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial// Eur. J. Endocrinol. -2020.- № 161.-С. 331–338.
34. Giustina, A. et all. Expert consensus document: A consensus on the medical treatment of acromegaly// Nat. Rev. Endocrinol.- 2014.- № 10.- С. 243–248.
35. Halupczok-Zyla J, Jawiarczyk-Przybylowska A & Bolanowski M. Patients with active acromegaly are at high risk of 25(OH)D deficiency. Frontiers in Endocrinology 2015, 6, 89.
36. Hong AR, Kim JH, Kim SW, Kim SY & Shin CS. Trabecular bone score as a skeletal fragility index in acromegaly patients. Osteoporosis International 2016 27 1123–1129.
37. Hoskuldsdottir GT, Fjalldal SB, Sigurjonsdottir H.A. The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013// Pituitary.- 2015.-№ 18.- С.803–807.
38. Hoskuldsdottir GT, Fjalldal SB, Sigurjonsdottir HA (2015) The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013. Pituitary 18:803–807
39. Kamenicky P, Mazziotti G, Lombes M, Giustina A & Chanson P. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocrine Reviews 2014 35 234–281.
40. Killinger Z. Osteoarticular changes in acromegaly // Int. J. Endocrinol. - 2012.-T. 2012.
41. Komori T. Runx2, an inducer of osteoblast and chondrocyte differentiation. Histochemistry and Cell Biology 2018 149 313–323.
42. Kuzma M, Vanuga P, Sagova I, Pavai D, Jackuliak P, Killinger Z, Binkley NC, Winzenrieth R, Genant HK & Payer J. Non-invasive DXA-derived bone structure assessment of acromegaly patients: a cross-sectional study. European Journal of Endocrinology 2019 180 201–211.
43. Lavrentaki Aikaterini , Alessandro Paluzzi, John A. H. Wass, and Niki Karavitaki. Epidemiology of acromegaly: review of population studies // Pituitary. 2017; 20(1): 4–9.
44. Lim SV, Marenzana M, Hopkinson M, List EO, Kopchick JJ, Pereira M, Javaheri B, Roux JP, Chavassieux P, Korbonits M et al. Excessive growth hormone expression in male GH transgenic mice adversely alters bone architecture and mechanical strength. Endocrinology 2015 156 1362–1371.
45. Madeira M, Neto LV, de Paula Paranhos Neto F, Barbosa Lima IC, Carvalho de Mendonca LM, Gadelha MR & Fleiuss de Farias ML. Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography. Journal of Clinical Endocrinology and Metabolism 2013, 98(4):1734–1741
46. Madeira M, Neto LV, Torres CH, de Mendonca LM, Gadelha MR & de Farias ML. Vertebral fracture assessment in acromegaly. Journal of Clinical Densitometry 2013 16 238–243.
47. Maffezzoni F, Maddalo M, Frara S, Mezzone M, Zorza I, Baruffaldi F, Doglietto F, Mazziotti G, Maroldi R & Giustina A. High-resolution- cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures.Endocrine 2016 54 532–542.
48. Maione L1, Chanson P2. National acromegaly registries. Best Pract Res Clin Endocrinol Metab. 2019 Mar 6. pii: S1521-690X(19)30007-7. doi: 10.1016/j.beem.2019.02.001.
49. Maridas DE, DeMambro VE, Le PT, Nagano K, Baron R, Mohan S & Rosen CJ. IGFBP-4 regulates adult skeletal growth in a sex-specific manner. Journal of Endocrinology 2017 233 131–144.
50. Maruotti N, Corrado A & Cantatore FP. Osteoblast role in osteoarthritis pathogenesis. Journal of Cellular Physiology 2017 232 2957–2963.
51. Mazziotti G, Biagioli E, Maffezzoni F, Spinello M, Serra V, Maroldi R, Floriani I & Giustina A. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2015 100 384–394.
52. Mazziotti G, Bianchi A, Porcelli T, Mormando M, Maffezzoni F, Cristiano A, Giampietro A, De Marinis L & Giustina A. Vertebral fractures in patients with acromegaly: a 3-year prospective study. Journal of Clinical Endocrinology and Metabolism 2013 98 3402–3410.
53. Mazziotti G, Gola M, Bianchi A, Porcelli T, Giampietro A, Cimino V, Doga M, Gazzaruso C, De Marinis L & Giustina A. Influence of diabetes mellitus on vertebral fractures in men with acromegaly.Endocrine 2011 40 102–108.
54. Mazziotti G, Maffezzoni F & Giustina A. Vitamin D-binding protein: one more piece in the puzzle of acromegalic osteopathy? Endocrine 2016, 52, 183–186.
55. Mazziotti Gherardo 1,2, Andrea G A Lania1,2 and Ernesto Canalis3 Bone disorders associated with acromegaly: mechanisms and treatment// European Journal of Endocrinology (2019) 181, R45–R56
56. Melmed S., F. F. Casanueva, A. Klibanski, M. D. Bronstein, P. Chanson, S. W. Lamberts, C. J. Strasburger, J. A. H. Wass, and A. Giustina A consensus on the diagnosis and treatment of acromegaly complicationsPituitary. 2013; 16(3): 294–302.
57. Melton L J, Riggs BL, Leibson CL , et al. A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab. 2008; 93:4804–4809.
58. Nicks KM, Amin S, Atkinson EJ, Riggs BL, Melton LJ 3rd, Khosla S. Relationship of age to bone microstructure independent of areal bone mineral density. J Bone Miner Res. 2012;27(3):637–644
59. Nishiyama KK, Macdonald HM, Buie HR, Hanley DA, Boyd SK. Postmenopausal women with osteopenia have higher cortical porosity and thinnercorticesatthedistalradiusandtibiathanwomen with normala BMD:aninvivoHR-pQCTstudy.JBoneMinerRes. 2010;25(4):882–890
60. Örük G, Tarhan F, Argın M, Özmen M. Is every joint symptom related to acromegaly? Endocrine. 2013; 43:404–411.
61. Ozer FF, Dagdelen S & Erbas T. Relation of RANKL and OPG levels with bone resorption in patients with acromegaly and prolactinoma. Hormone and Metabolic Research 2018 50 562–567.
62. Romijn JA. Acromegalic arthropathy: current perspectives. Endocrine. 2013; 43:245–246.
63. Silva PPB, Amlashi FG, Yu EW, Pulaski-Liebert KJ, Gerweck AV, Fazeli PK, Lawson E, Nachtigall LB, Biller BMK, Miller KK et al. Bone microarchitecture and estimated bone strength in men with active acromegaly. European Journal of Endocrinology 2017 177 409–420.
64. Siris ES, Genant HK, Laster AJ, Chen P, Misurski DA, Krege JH 2007 Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporos Int 18:761–770
65. Tjörnstrand A., Gunnarsson K., Evert M., Holmberg E., Ragnarsson O., Rosén T., Filipsson Nyström H. The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011 // Eur J Endocrinol. - 2014. - № 171 (4). – Р. 519–526.
66. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis. Osteoporos Int . 2007;18:427–444.
67. Wassenaar M. J. E., Biermasz N. R., Hamdy N. A. T. et al., “High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly,” European Journal of Endocrinology, vol. 164, no. 4, pp. 475–483, 2011
68. Xi G, Wai C, DeMambro V, Rosen CJ & Clemmons DR. IGFBP-2 directly stimulates osteoblast differentiation. Journal of Bone and Mineral Research 2014 29 2427–2438.
69. Yamamoto M, Yamaguchi T, Yamauchi M , Kaji H , Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res. 2009; 24:702–709.
70. Zamira Y. Khalimova, Adliya O. Kholikova, Umida A. Mirsaidova, Dildora H. Abidova Prevalence of Acromegaly in the Republic of Uzbekistan American Journal of Medicine and Medical Sciences p-ISSN: 2165-901X e-ISSN: 2165-9036 2019; 9(8): 293-297/
71. Zdenko Killinger, Martin Kuzˇma, Lenka Sterancˇa´kova´, and Juraj Payer. Osteoarticular Changes in Acromegaly //International Journal of Endocrinology Volume 2012, Article ID 839282, 7 pages doi:10.1155/2012/839282
72. Zgliczynski W, Kochman M, Misiorowski W, Zdunowski P 2007 In acromegaly, increased bone mineral density (BMD) is determined by GH excess, gonadal function and gender. Neuro Endocrinol Lett 28:621–628
2. Молитвословова Н. Н. ФГУ Эндокринологический научный центр Минздравсоцразвития Российской Федерации // Проблемы эндокринологии. - 2011. - №57(1).- С. 46-59.
3. Потешкин Ю.Е. «Композиционный состав тела (тощая, жировая и костная ткань) и минеральная плотность костей у больных акромегалией» Диссерт на соиск. Уч. Ст. канд.м.н., Москва, 2014, стр 13-15
4. Пронин В.С., Пронин Е.В. Международные консенсусные соглашения по диагностике и лечению акромегалии // Аналитические обзоры: Эндокринология: новости, мнения, обучение. - 2019. - Том 8, № 1.
5. Самородская И.В., Болотова Е. В., Бойцов С. А. Актуальные вопросы классификации ожирения //Cardiovascular Therapy and Prevention, 2015; 14(4): 103–110
6. Холикова А.О. Соматотропиномы: клинико-эпидемиологические аспекты, частота осложнений, оценка эффективности лечения по Республике Узбекистан //Автореферат на диссертационную работу. - 2019. - С. 7-12.
7. Чих И.Д., Триголосова И.В., Древаль А.В., Триголосов А.В. Новообразования при акромегалии // Альманах клинической медицины. 2016.- №44 (5). - С. 568–579.
8. Abreu A, Tovar AP, Castellanos R, Valenzuela A, Giraldo CM, Pinedo AC, Guerrero DP, Barrera CA, Franco HI, Ribeiro-Oliveira A Jr, Vilar L, Jallad RS, Duarte FG, Gadelha M, Boguszewski CL, Abucham J, Naves LA, Musolino NR, de Faria ME, Rossato C, Bronstein MD (2016) Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary 19(4):448–457
9. Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, Thorsson AV, Carroll PV, Korbonits M, Benediktsson R (2015) The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. Eur J Endocrinol 173(5):655–664.
10. Ajmal A, Haghshenas A, Attarian S, Barake M, Tritos NA, Klibanski A, Miller KK & Nachtigall LB. The effect of somatostatin analogs on vitamin D and calcium concentrations in patients with acromegaly. Pituitary 2014 17 366–373
11. Altinova AE, Ozkan C, Akturk M, Gulbahar O, Yalcin M, Cakir N & Toruner FB. Vitamin D-binding protein and free vitamin Dconcentrations in acromegaly. Endocrine 2016 52 374–379.
12. Andrea Giustina, Gherardo Mazziotti, and Ernesto Canalis Growth Hormone, Insulin-Like Growth Factors, and the Skeleton/ Endocr Rev. 2008 Aug; 29(5): 535–559.
13. Ariel L. Barkan. Acromegalic Arthropathy// Pituitary 4: 263–264, 2001.
14. Arosio M, Emerging trends in the diagnosis and treatment of acromegaly in Canada // Clin Endocrinol (Oxf). - 2013.- Jul; 79(1).- С.79-85.
15. Arosio M, Reimondo G, Malchiodi E et al (2012) Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 167(2):189–198
16. Belaya Z, Grebennikova T, Melnichenko G, Nikitin A, Solodovnikov A, Brovkina O, Grigoriev A, Rozhinskaya L, Lutsenko A & Dedov I. Effects of active acromegaly on bone mRNA and microRNA expression patterns. European Journal of Endocrinology 2018 178 353–364.
17. Ben-Shlomo A., M. C. Sheppard, J. M. Stephens, S. Pulgar, and S. Melmed Clinical, quality of life, and economic value of acromegaly disease control/ Pituitary. 2011 September; 14(3): 284–294.
18. Biermasz N. R., Van Thiel S. W., Pereira A. M. et al., “Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 11, pp. 5369–5376, 2004.
19. Burghardt AJ, Issever AS, Schwartz AV , et al. . High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab . 2010;95(11):5045–5055.
20. Canalis E The fate of circulating osteoblasts. N Engl J Med 2005; 352:2014–2016
21. Capatina C, Wass J.A. 60 years of neuroendocrinology: acromegaly// J Endocrinol. - 2015.-№ 226.- С.141–160.
22. Colao A, Grasso LFS, Giustina A, Melmed S . et all. Acromegaly// Nat Rev Dis Primers.- 2019.- № 5(1).- С.20-24
23. Constantin T, Tangpricha V, Shah R, Oyesiku NM, Ioachimescu OC, Ritchie J & Ioachimescu AG. Calcium and bone turnover markers in acromegaly: a prospective, controlled study. Journal of Clinical Endocrinology and Metabolism 2017 102 2416–2424.
24. Dal J, Feldt-Rasmussen U, Andersen M, Kristensen LØ. et all. Acromegaly incidence, prevalence, complications, and long-term prognosis: a nationwide cohort study // Eur J Endocrinol.- 2016.- 175(3). С.181-190.
25. Dal J, List E.O, Jørgensen JO, Berryman D.E Glucose and fat metabolism in acromegaly: from mice models to patient care// Neuroendocrinology.- 2016.-№103(1).- С.96–105.
26. Dalle Carbonare L, Micheletti V, Cosaro E, Valenti MT, Mottes M, Francia G & Davi MV. Bone histomorphometry in acromegaly patients with fragility vertebral fractures. Pituitary 2018 21 56–2164.
27. Dalzell N, Kaptoge S, Morris N, et al. Bonemicro-architecture and determinants of strength intheradius and tibia: age-relatedchanges in a population-based study of normal adults measured with highresolution pQCT. Osteoporos Int. 2009;20(10):1683–1694.
28. De Mambro VE, Le PT, Guntur AR, Maridas DE, Canalis E, Nagano K, Baron R, Clemmons DR & Rosen CJ. Igfbp2 deletion in ovariectomized mice enhances energy expenditure but accelerates bone loss. Endocrinology 2015 156 4129–4140.
29. Dreval A.V., Trigolosova I.V., Misnikova I.V. et all. Prevalence of diabetes mellitus in patients with acromegaly// Endocr Connect.- 2014.-№ 3.-С.93–98
30. Gadelha MR, Kasuki L, Lim DST, Fleseriu M. Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update// Endocr Rev.- 2019.- 40(1).-С.268-332.
31. Giuseppina P., Graziella B., Laura I. et al., “Prevalence of osteoporosis and vertebral fractures in acromegalic patients,” Clinical Cases in Mineral and Bone Metabolism, vol. 8, no. 3, pp. 37–43, 2011.
32. Giustina A, Chanson P, Bronstein MD, Klibanski A. et all. A consensus on criteria for cure of acromegaly// J Clin Endocrinol Metab. - 2010.-95 (7).-С. 3141–3148.
33. Giustina, A. et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial// Eur. J. Endocrinol. -2020.- № 161.-С. 331–338.
34. Giustina, A. et all. Expert consensus document: A consensus on the medical treatment of acromegaly// Nat. Rev. Endocrinol.- 2014.- № 10.- С. 243–248.
35. Halupczok-Zyla J, Jawiarczyk-Przybylowska A & Bolanowski M. Patients with active acromegaly are at high risk of 25(OH)D deficiency. Frontiers in Endocrinology 2015, 6, 89.
36. Hong AR, Kim JH, Kim SW, Kim SY & Shin CS. Trabecular bone score as a skeletal fragility index in acromegaly patients. Osteoporosis International 2016 27 1123–1129.
37. Hoskuldsdottir GT, Fjalldal SB, Sigurjonsdottir H.A. The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013// Pituitary.- 2015.-№ 18.- С.803–807.
38. Hoskuldsdottir GT, Fjalldal SB, Sigurjonsdottir HA (2015) The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013. Pituitary 18:803–807
39. Kamenicky P, Mazziotti G, Lombes M, Giustina A & Chanson P. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocrine Reviews 2014 35 234–281.
40. Killinger Z. Osteoarticular changes in acromegaly // Int. J. Endocrinol. - 2012.-T. 2012.
41. Komori T. Runx2, an inducer of osteoblast and chondrocyte differentiation. Histochemistry and Cell Biology 2018 149 313–323.
42. Kuzma M, Vanuga P, Sagova I, Pavai D, Jackuliak P, Killinger Z, Binkley NC, Winzenrieth R, Genant HK & Payer J. Non-invasive DXA-derived bone structure assessment of acromegaly patients: a cross-sectional study. European Journal of Endocrinology 2019 180 201–211.
43. Lavrentaki Aikaterini , Alessandro Paluzzi, John A. H. Wass, and Niki Karavitaki. Epidemiology of acromegaly: review of population studies // Pituitary. 2017; 20(1): 4–9.
44. Lim SV, Marenzana M, Hopkinson M, List EO, Kopchick JJ, Pereira M, Javaheri B, Roux JP, Chavassieux P, Korbonits M et al. Excessive growth hormone expression in male GH transgenic mice adversely alters bone architecture and mechanical strength. Endocrinology 2015 156 1362–1371.
45. Madeira M, Neto LV, de Paula Paranhos Neto F, Barbosa Lima IC, Carvalho de Mendonca LM, Gadelha MR & Fleiuss de Farias ML. Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography. Journal of Clinical Endocrinology and Metabolism 2013, 98(4):1734–1741
46. Madeira M, Neto LV, Torres CH, de Mendonca LM, Gadelha MR & de Farias ML. Vertebral fracture assessment in acromegaly. Journal of Clinical Densitometry 2013 16 238–243.
47. Maffezzoni F, Maddalo M, Frara S, Mezzone M, Zorza I, Baruffaldi F, Doglietto F, Mazziotti G, Maroldi R & Giustina A. High-resolution- cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures.Endocrine 2016 54 532–542.
48. Maione L1, Chanson P2. National acromegaly registries. Best Pract Res Clin Endocrinol Metab. 2019 Mar 6. pii: S1521-690X(19)30007-7. doi: 10.1016/j.beem.2019.02.001.
49. Maridas DE, DeMambro VE, Le PT, Nagano K, Baron R, Mohan S & Rosen CJ. IGFBP-4 regulates adult skeletal growth in a sex-specific manner. Journal of Endocrinology 2017 233 131–144.
50. Maruotti N, Corrado A & Cantatore FP. Osteoblast role in osteoarthritis pathogenesis. Journal of Cellular Physiology 2017 232 2957–2963.
51. Mazziotti G, Biagioli E, Maffezzoni F, Spinello M, Serra V, Maroldi R, Floriani I & Giustina A. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2015 100 384–394.
52. Mazziotti G, Bianchi A, Porcelli T, Mormando M, Maffezzoni F, Cristiano A, Giampietro A, De Marinis L & Giustina A. Vertebral fractures in patients with acromegaly: a 3-year prospective study. Journal of Clinical Endocrinology and Metabolism 2013 98 3402–3410.
53. Mazziotti G, Gola M, Bianchi A, Porcelli T, Giampietro A, Cimino V, Doga M, Gazzaruso C, De Marinis L & Giustina A. Influence of diabetes mellitus on vertebral fractures in men with acromegaly.Endocrine 2011 40 102–108.
54. Mazziotti G, Maffezzoni F & Giustina A. Vitamin D-binding protein: one more piece in the puzzle of acromegalic osteopathy? Endocrine 2016, 52, 183–186.
55. Mazziotti Gherardo 1,2, Andrea G A Lania1,2 and Ernesto Canalis3 Bone disorders associated with acromegaly: mechanisms and treatment// European Journal of Endocrinology (2019) 181, R45–R56
56. Melmed S., F. F. Casanueva, A. Klibanski, M. D. Bronstein, P. Chanson, S. W. Lamberts, C. J. Strasburger, J. A. H. Wass, and A. Giustina A consensus on the diagnosis and treatment of acromegaly complicationsPituitary. 2013; 16(3): 294–302.
57. Melton L J, Riggs BL, Leibson CL , et al. A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab. 2008; 93:4804–4809.
58. Nicks KM, Amin S, Atkinson EJ, Riggs BL, Melton LJ 3rd, Khosla S. Relationship of age to bone microstructure independent of areal bone mineral density. J Bone Miner Res. 2012;27(3):637–644
59. Nishiyama KK, Macdonald HM, Buie HR, Hanley DA, Boyd SK. Postmenopausal women with osteopenia have higher cortical porosity and thinnercorticesatthedistalradiusandtibiathanwomen with normala BMD:aninvivoHR-pQCTstudy.JBoneMinerRes. 2010;25(4):882–890
60. Örük G, Tarhan F, Argın M, Özmen M. Is every joint symptom related to acromegaly? Endocrine. 2013; 43:404–411.
61. Ozer FF, Dagdelen S & Erbas T. Relation of RANKL and OPG levels with bone resorption in patients with acromegaly and prolactinoma. Hormone and Metabolic Research 2018 50 562–567.
62. Romijn JA. Acromegalic arthropathy: current perspectives. Endocrine. 2013; 43:245–246.
63. Silva PPB, Amlashi FG, Yu EW, Pulaski-Liebert KJ, Gerweck AV, Fazeli PK, Lawson E, Nachtigall LB, Biller BMK, Miller KK et al. Bone microarchitecture and estimated bone strength in men with active acromegaly. European Journal of Endocrinology 2017 177 409–420.
64. Siris ES, Genant HK, Laster AJ, Chen P, Misurski DA, Krege JH 2007 Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporos Int 18:761–770
65. Tjörnstrand A., Gunnarsson K., Evert M., Holmberg E., Ragnarsson O., Rosén T., Filipsson Nyström H. The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011 // Eur J Endocrinol. - 2014. - № 171 (4). – Р. 519–526.
66. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis. Osteoporos Int . 2007;18:427–444.
67. Wassenaar M. J. E., Biermasz N. R., Hamdy N. A. T. et al., “High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly,” European Journal of Endocrinology, vol. 164, no. 4, pp. 475–483, 2011
68. Xi G, Wai C, DeMambro V, Rosen CJ & Clemmons DR. IGFBP-2 directly stimulates osteoblast differentiation. Journal of Bone and Mineral Research 2014 29 2427–2438.
69. Yamamoto M, Yamaguchi T, Yamauchi M , Kaji H , Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res. 2009; 24:702–709.
70. Zamira Y. Khalimova, Adliya O. Kholikova, Umida A. Mirsaidova, Dildora H. Abidova Prevalence of Acromegaly in the Republic of Uzbekistan American Journal of Medicine and Medical Sciences p-ISSN: 2165-901X e-ISSN: 2165-9036 2019; 9(8): 293-297/
71. Zdenko Killinger, Martin Kuzˇma, Lenka Sterancˇa´kova´, and Juraj Payer. Osteoarticular Changes in Acromegaly //International Journal of Endocrinology Volume 2012, Article ID 839282, 7 pages doi:10.1155/2012/839282
72. Zgliczynski W, Kochman M, Misiorowski W, Zdunowski P 2007 In acromegaly, increased bone mineral density (BMD) is determined by GH excess, gonadal function and gender. Neuro Endocrinol Lett 28:621–628
Published
2022-06-18
How to Cite
Юсуповна, Х. З., Шарифовна, Х. Д., Машариповна, С. Ш., Убайдуллаевна, М. С., & кизи, И. Г. К. (2022). Вопросы Патогенеза Опорно-Двигательных Осложнений Акромегалии. Central Asian Journal of Medical and Natural Science, 3(3), 661-674. https://doi.org/10.17605/cajmns.v3i3.834
Issue
Section
Articles
